askg712
Recombinant proteinexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 28, 2022 (NCT05345769)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Vascular endothelial growth factor AANTAGONIST
VEGF
- Angiopoietin-2ANTAGONIST
ANGPT2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05940428 | Phase 1 | Jul 30, 2023 | AskGene Pharma, Inc., Chinese Academy of Medical Sciences, Suzhou Aosaikang Biopharmaceutical Co., Ltd. |
| NCT05456828 | Phase 1 | Jul 31, 2022 | AskGene Pharma, Inc., Jiao Tong University, Suzhou Aosaikang Biopharmaceutical Co., Ltd. |
| NCT05345769 | Phase 1 | Apr 28, 2022 | AffaMed Therapeutics (US) Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AskGene Pharma, Inc. | For profit | 2 | 2 | 1 | 2022 |
| Suzhou Aosaikang Biopharmaceutical Co., Ltd. | For profit | 2 | 0 | 1 | 2022 |
| AffaMed Therapeutics (US) Inc. | For profit | 1 | 1 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1